105 related articles for article (PubMed ID: 22587883)
1. Transforming growth factor (TGF)-β expression and activation mechanisms as potential targets for anti-tumor therapy and tumor imaging.
Arjaans M; Oude Munnink TH; Timmer-Bosscha H; Reiss M; Walenkamp AM; Lub-de Hooge MN; de Vries EG; Schröder CP
Pharmacol Ther; 2012 Aug; 135(2):123-32. PubMed ID: 22587883
[TBL] [Abstract][Full Text] [Related]
2. Exploring anti-TGF-β therapies in cancer and fibrosis.
Hawinkels LJ; Ten Dijke P
Growth Factors; 2011 Aug; 29(4):140-52. PubMed ID: 21718111
[TBL] [Abstract][Full Text] [Related]
3. Role of transforming growth factor-beta in cancer progression.
Galliher AJ; Neil JR; Schiemann WP
Future Oncol; 2006 Dec; 2(6):743-63. PubMed ID: 17155901
[TBL] [Abstract][Full Text] [Related]
4. Targeting the transforming growth factor-beta signalling pathway in metastatic cancer.
Korpal M; Kang Y
Eur J Cancer; 2010 May; 46(7):1232-40. PubMed ID: 20307969
[TBL] [Abstract][Full Text] [Related]
5. TGF-β as a therapeutic target in high grade gliomas - promises and challenges.
Joseph JV; Balasubramaniyan V; Walenkamp A; Kruyt FA
Biochem Pharmacol; 2013 Feb; 85(4):478-85. PubMed ID: 23159669
[TBL] [Abstract][Full Text] [Related]
6. The role for transforming growth factor-beta (TGF-beta) in human cancer.
Gold LI
Crit Rev Oncog; 1999; 10(4):303-60. PubMed ID: 10654929
[TBL] [Abstract][Full Text] [Related]
7. The dynamic roles of TGF-β in cancer.
Meulmeester E; Ten Dijke P
J Pathol; 2011 Jan; 223(2):205-18. PubMed ID: 20957627
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.
Medicherla S; Li L; Ma JY; Kapoun AM; Gaspar NJ; Liu YW; Mangadu R; O'Young G; Protter AA; Schreiner GF; Wong DH; Higgins LS
Anticancer Res; 2007; 27(6B):4149-57. PubMed ID: 18229422
[TBL] [Abstract][Full Text] [Related]
9. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
10. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy.
Kim R; Emi M; Tanabe K; Uchida Y; Toge T
Cancer; 2004 Jun; 100(11):2281-91. PubMed ID: 15160330
[TBL] [Abstract][Full Text] [Related]
11. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo.
Moore LD; Isayeva T; Siegal GP; Ponnazhagan S
Clin Cancer Res; 2008 Aug; 14(15):4961-70. PubMed ID: 18676771
[TBL] [Abstract][Full Text] [Related]
12. Large- and small-molecule inhibitors of transforming growth factor-beta signaling.
Akhurst RJ
Curr Opin Investig Drugs; 2006 Jun; 7(6):513-21. PubMed ID: 16784021
[TBL] [Abstract][Full Text] [Related]
13. TGF-beta signaling in tumor suppression and cancer progression.
Derynck R; Akhurst RJ; Balmain A
Nat Genet; 2001 Oct; 29(2):117-29. PubMed ID: 11586292
[TBL] [Abstract][Full Text] [Related]
14. Role of TGF-beta in cancer and the potential for therapy and prevention.
Kaklamani VG; Pasche B
Expert Rev Anticancer Ther; 2004 Aug; 4(4):649-61. PubMed ID: 15270668
[TBL] [Abstract][Full Text] [Related]
15. Development of TGF-beta signalling inhibitors for cancer therapy.
Yingling JM; Blanchard KL; Sawyer JS
Nat Rev Drug Discov; 2004 Dec; 3(12):1011-22. PubMed ID: 15573100
[TBL] [Abstract][Full Text] [Related]
16. A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential.
Fritzmann J; Morkel M; Besser D; Budczies J; Kosel F; Brembeck FH; Stein U; Fichtner I; Schlag PM; Birchmeier W
Gastroenterology; 2009 Jul; 137(1):165-75. PubMed ID: 19328798
[TBL] [Abstract][Full Text] [Related]
17. Proteomics of TGF-beta signaling and its impact on breast cancer.
Souchelnytskyi S
Expert Rev Proteomics; 2005 Dec; 2(6):925-35. PubMed ID: 16307521
[TBL] [Abstract][Full Text] [Related]
18. Cathepsin G-mediated activation of pro-matrix metalloproteinase 9 at the tumor-bone interface promotes transforming growth factor-beta signaling and bone destruction.
Wilson TJ; Nannuru KC; Singh RK
Mol Cancer Res; 2009 Aug; 7(8):1224-33. PubMed ID: 19671689
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression.
Maluccio M; Sharma V; Lagman M; Vyas S; Yang H; Li B; Suthanthiran M
Transplantation; 2003 Aug; 76(3):597-602. PubMed ID: 12923450
[TBL] [Abstract][Full Text] [Related]
20. Sonic hedgehog signaling promotes motility and invasiveness of gastric cancer cells through TGF-beta-mediated activation of the ALK5-Smad 3 pathway.
Yoo YA; Kang MH; Kim JS; Oh SC
Carcinogenesis; 2008 Mar; 29(3):480-90. PubMed ID: 18174246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
